Fasudi, which is commonly used to improve microvascular dysfunction, has been shown to exert protective effects on streptozotocin-induced diabetic nephropathy by blocking the VEGFR2/Src/caveolin-1 signaling pathway, suggesting that caveolin-1 could be targeted to ameliorate microvascular dysfunction [87]. The gene discussed is CAV1; the disease is diabetic kidney disease.